Core Cap Advisors, LLC Galectin Therapeutics Inc Transaction History
Core Cap Advisors, LLC
- $2.18 Billion
- Q1 2025
A detailed history of Core Cap Advisors, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Core Cap Advisors, LLC holds 4,594 shares of GALT stock, worth $6,018. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,594
Previous 8,399
45.3%
Holding current value
$6,018
Previous $9,000
44.44%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding GALT
# of Institutions
103Shares Held
10.1MCall Options Held
587KPut Options Held
2.02M-
Vanguard Group Inc Valley Forge, PA2.19MShares$2.87 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$2.05 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.22MShares$1.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA853KShares$1.12 Million0.0% of portfolio
-
Geneos Wealth Management Inc.423KShares$554,4370.02% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $77.8M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...